**Poster Abstracts from LNTN members**

**THU0246**

**ROLE OF IGE IN THE PATHOGENESIS OF TUBULOINTERSTITIAL INFLAMMATION IN HUMAN LUPUS NEPHRITIS.**

V. M. Liarski1,\*, J. Henault2, R. Herbst2, R. Kolbeck2, M. Sanjuan2, M. R. Clark1

**THU0287**

**GLUCOCORTICOIDS WITHDRAWAL IN SYSTEMIC LUPUS ERYTHEMATOSUS: MYTH O REALITY?**

C. Tani1,\*, L. Carli1,2, R. Vagelli1, V. Signorini1, S. Vagnani1, D. Totti1, M. Tristano1, M. Mosca1

**THU0303**

**LONGITUDINAL PATTERNS IN SLE RESPONSE TO STANDARD OF CARE THERAPY: IMPLICATIONS FOR SLE CLINICAL TRIAL DESIGN**

M. Kim1,\*, J. T. Merrill2, K. C. Kalunian 3, B. H. Hahn4, A. Roach5, P. M. Izmirly 6 on behalf of The Lupus Foundation of America Collective Data Analysis Initiative Group

**THU0304**

**ADHERENCE TO HYDROXYCHLOROQUINE AS ASSESSED BY MEASUREMENTS OF DRUG AND METABOLITE BLOOD LEVELS IN AN INTERNATIONAL PROSPECTIVE STUDY OF SLE PATIENTS IN FLARE.**

N. Costedoat-Chalumeau1,\*, F. Houssiau 2, P. Izmirly3, V. Le Guern1, S. Navarra4, M. Jolly3, G. Ruiz-Irastorza5, E. Hachulla1, N. Agmon-Levin6, Y. Shoenfeld6, F. Dall'Ara7, J. Buyon3, C. Deligny1, R. Cervera5, E. Lazaro1, H. Bezanahary1, G. Leroux1, N. Morel1, J.-F. Viallard1, C. Pineau8, L. Galicier1, R. Van Vollenhoven9, A. Tincani7, H. Nguyen10, G. Gondran1, N. Zahr1, J. Pouchot1, J.-C. Piette1, M. Petri3, D.Isenberg10

**THU0317**

**TUBULOINSTERSTIAL DAMAGE IS AN INDEPENDENT PREDICTOR OF END STAGE RENAL DISEASE IN LUPUS NEPHRITIS PATIENTS WITH MILD TO MODERATE RENAL IMPAIRMENT.**

B. Jovanovic1, H. N. Khan1, W. Mowrey1, P. Izmirly2, D. Schwartz1, J. Buyon2, C. Putterman1, B. Goilav1, A. Broder1,\*

**THU0355**

**CLINICAL TRIAL SIMULATION IDENTIFIES FACTORS FOR PATIENT ENGAGEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS TRIALS IN AFRICAN-AMERICANS**

S. S. Lim1,\*, D. McKinnell2, M. E. Pierson3, F. S. O'Brien3

**FRI0310**

**SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NEPHRITIS**

I. Parodis1,\*, H. Ding2, A. Zickert1, L. Arnaud1, C. Mohan2, I. Gunnarsson1

**FRI0312**

**PREDICTORS OF INCIDENT EPISODES OF PROTEINURIA AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

L. S. Magder1, A. Duarte-Garcia2, E. Barr1, M. Petri3

**FRI0336**

**HYPOCOMPLEMENTEMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS; ESTABLISHING THE IMPORTANCE OF LOW C3 AND C4 IN A LONGITUDINAL COHORT.**

L. Durcan1,2,\*, W. Fu1, M. Petri1

**FRI0506**

**PREGNANCY IN PATIENTS WITH UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: CLINICAL OUTCOMES IN 78 CASES**

R. Vagelli1,\*, C. Tani1, L. Carli1,2, D. Totti1, M. Tristano1, F. Strigini1, M. Mosca1

**SAT0255**

**PROSPECTIVE STUDY: THE ROLE OF URINARY HER2 AS A LUPUS NEPHRITIS BIOMARKER**

P. Costa Reis1,2,3,4,\*, K. Dietzmann-Maurer3, E. Von Scheven5, J. M. Burnham6, K. E. Sullivan3,4

**Abstracts for Publication from LNTN members**

**AB0001**

**GENETIC VARIANTS IN IL-12B AND IL-27 IN THE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

A.Paradowska-Gorycka1,\*, A. Sowinska2, B. Stypinska1, M. Grobelna3, M. Walczyk4, M. Olesinska4, P. Piotrowski5, P. P. Jagodzinski3

**AB0004**

**POLYMORPHISMS IN GENES IN THE IL-17 PATHWAY AND B CELL MEDIATED IMMUNE RESPONSE MODULATE THE DEVELOPMENT OF SPECIFIC AUTOIMMUNE MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS**

C. Perricone1,\*, C. Ciccacci2, F. Ceccarelli1, E. Cipriano1, C. Alessandri1, F. R. Spinelli1, S. Rufini2, C. Politi2, A. Latini2, G. Novelli2, G.Valesini1, P. Borgiani2, F. Conti1

**AB0013**

**GLOMERULAR IL-4 SIGNALING MEDIATES FOOT PROCESS EFFACEMENT AND PROTEINURIA IN NEPHROTIC SYNDROMES**

A. H. Kim1,\*, S. Akilesh2, A. Koziell3, B. Saunders4, S. Jain5, J. Hodgin6, B. Zinselmeyer4, T. Stappenback4, J. Miner5, A. Shaw7

**AB0407**

**CAN WE IDENTIFY WHO BENEFITS FROM MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS? A SYSTEMATIC REVIEW**

C. Mendoza Pinto1,2,\*, C. Pirone2,3, B. Parker2, I. Bruce2

**AB0419**

**AURION STUDY: PRELIMINARY RESULTS OF VOCLOSPORIN IN LUPUS NEPHRITIS**

R. Yahya1, A. H. B. A. Gafor2, R. Huizinga3,\*, T. M. Chan4, N. Solomons3

**AB0423**

**NOBILITY, A PHASE 2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OBINUTUZUMAB, A NOVEL TYPE 2 ANTI-CD20 MONOCLONAL ANTIBODY (MAB), IN PATIENTS (PTS) WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS (LN)**

T. Schindler1,\*, B. Rovin2, R. Furie3, M. Leandro4, M. Clark5, P. Brunetta6, J. Garg6

**AB0425**

**TAC-TIC USE OF TACROLIMUS-BASED REGIMENS IN LUPUS NEPHRITIS**

T. Kraaij1,\*, O. W. Bredewold1, T. Huizinga2, T. Rabelink1, O. Teng1

**AB0436**

**ALL THE “HISPANICS” ARE NOT EQUAL. THE SEVERITY AND ACTIVITY OF PATIENTS WITH SLE IS HIGHER IN MESTIZOS LATIN AMERICAN VS. EUROPEAN CAUCASIAN. LESSONS FROM RELESSER.**

B. Hernández-Cruz1,\*, F. Alonso2, J. Calvo Alén3, J. M. Pego-Reigosa4, F. J. López-Longo5, M. Galindo Izquierdo6, A. Olive7, E. Tomero8, Í. Rúa-Figeroa9 on behalf of On behalf of RELESSER group.

**AB0458**

**SERUM FERRITIN AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL RESPONSE TO TREATMENT IN LUPUS NEPHRITIS**

I. Parodis1,\*, H. Ding2, A. Zickert1, L. Arnaud1, C. Mohan2, I. Gunnarsson1

**AB0479**

**MUSCULOSKELETAL MANIFESTATIONS ARE MAJOR DETERMINANTS OF IMPAIRED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.**

M. Piga1,\*, M. Congia1, A. Floris1,2, A. Gabba1, A. Cauli1, A. Mathieu1

**AB0512**

**USE OF NOMINAL GROUP TECHNIQUE TO FACILITATE ITEM REDUCTION FOR SLE CLASSIFICATION CRITERIA DEVELOPMENT**

S. Johnson1,\*, D. Khanna2, R. Cervera3, N. Costedoat-Chalumeau4, D. D. Gladman1, B. H. Hahn5, F. Hiepe6, J. Sanchez-Guerrero1,7, E.Massarotti8, D. Boumpas9, K. Costenbader8, D. Daikh10, D. Jayne11, T. Dorner12, D. Kamen13, M. Mosca14, R. Ramsey-Goldman15, J. S.Smolen16, D. Wofsy10, M. Aringer17

**AB0513**

**PREGNANCY OUTCOME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

O. N. Pamuk1, M. A. BAlci1, N. Yilmaz2, S. Yavuz2

**Abstracts for Oral Presentation from LNTN members**

**OP0164**

**BLOCKADE OF IMMUNE COMPLEX-MEDIATED GLOMERULONEPHRITIS BY HIGHLY SELECTIVE INHIBITION OF BRUTON’S TYROSINE KINASE**

S. A. Chalmers1,\*, J. Doerner1, T. Bosanac2, S. Khalil2, D. Smith2, C. Harcken2, J. Dimock2, E. Der1, L. Herlitz3, D. Webb2, E. Seccareccia2, D. Feng2, J. S. Fine2, M. Ramanujam2, E. Klein2, C. Putterman1

**OP0188**

**THE DOSE OF GLUCOCORTICOIDS TAKEN AT ONE YEAR, BUT NOT THE INITIAL DOSE PRESCRIBED, IS AN INDEPENDENT PREDICTOR OF DAMAGE ACCRUAL IN LUPUS NEPHRITIS.**

A.El Mourad1, S. Nieuwland-Husson1, G. Depresseux1, F. A. Houssiau1,